Caremark Rx Inc

Caremark Rx — Advancepcs — Merger or Acquisition (March 2004)

30 slides from Caremark Rx's merger presentation, Mar 3, 2004

  1. Slide 1: Caremark Rx, Inc. and AdvancePCS Investor Presentation

    Caremark Rx, Inc. AdvancePCS Investor Presentation March 3, 2004

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements contained in this presentation constitute forward-looking statements contemplated under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding benefits of the proposed merger and expected syner

  3. Slide 3: Agenda

    Agenda • Introduction • Merger Overview Transaction Terms Timetable Update Combination Benefits • AdvancePCS Recent Financial Performance • Caremark Rx Recent Financial Performance • Q&A

  4. Slide 4: Merger Overview

    Merger Overview

  5. Slide 5: Key Transaction Terms

    Key Transaction Terms Per share consideration: Value equivalent to 2.15 Caremark shares per AdvancePCS share Consideration mix: 90% stock / 10% cash Transaction structure: Tax-free reorganization, excluding cash component Conditions to closing: · Caremark and AdvancePCS stockholder approval · Custom

  6. Slide 6: Merger Timing Update

    Merger Timing Update • September 2, 2003 Merger Announced • September 10, 2003 Initial HSR Filing • October 6, 2003 S-4/Joint Proxy Filed with SEC - • October 10, 2003 Requests for additional Information from FTC • February 11, 2004 Termination of HSR by FTC • February 13, 2004 S-4 declared effectiv

  7. Slide 7: Strategic Benefits

    Strategic Benefits • Enhanced provider of health management solutions • Highly complementary businesses Increased customer diversity Recognized expertise in mail service and retail programs Broader specialty programs Comprehensive disease management solutions • Expertise in driving preference for ma

  8. Slide 8: Complementary Customer Mix

    Complementary Customer Mix Caremark will apply best practices from both organizations to focus on the particular needs of clients within each client segment Caremark Health Plans Employer/ Government AdvancePCS 1 Health Plans Employer/ Government Combined 1 Employer/ Government Health Plans 1 Exclud

  9. Slide 9: Enhanced Customer Value

    Enhanced Customer Value Expanded size and scope expected to provide enhanced value for clients • Caremark will be in a position to offer enhanced value for clients as a large, diversified, independent PBM • Combined companies processed over 600 million prescriptions in the twelve months ended Decemb

  10. Slide 10: Broader Choice and Convenience for Customers

    Broader Choice and Convenience for Customers Headquarters Specialty Pharmacy Business Center Mail Service Pharmacy Call Center Note: Blue symbol represents AdvancePCS facility Red symbol represents Caremark facility

  11. Slide 11: Premier Specialty Programs

    Premier Specialty Programs • 25 years of experience • Key therapies: Hemophilia Growth Hormone Multiple Sclerosis Hepatitis C RSV • TheraCom key therapies: Pulmonary hypertension Gaucher disease Fabry disease Hurler’s syndrome Multiple Sclerosis • Expanded specialty product line • Access to large ma

  12. Slide 12: Complementary Disease Management

    Complementary Disease Management • CarePatterns Programs: Asthma * * Pediatric Asthma CAD * * CHF * * COPD Diabetes * * Ulcer Hemophilia • Accordant Health: Seizures* RA* Parkinson’s* Scleroderma* Hemophilia* Sickle cell anemia* Systemic lupus* ALS* Dermatomyositis* Cystic fibrosis* Gaucher* Multipl

  13. Slide 13: Enhanced Mail Order Opportunity

    Enhanced Mail Order Opportunity • Transaction expected to expand opportunities for further penetration of mail order services Increases safety, compliance and convenience Provides savings for clients and members • Consistent technology in each company’s state of the art mail facilities Mail Penetrat

  14. Slide 14: Overview of Expected Financial Benefits

    Overview of Expected Financial Benefits • Expected to be accretive to Caremark Rx EPS in the near term •$ 125 million in expected synergies in first year following closing with a majority coming through purchasing efficiencies • The combined company is anticipated to have a strong balance sheet with

  15. Slide 15: Transaction Summary

    Transaction Summary • Enhanced provider of health management solutions • Highly complementary businesses Increased customer diversity with over 600 million prescriptions in the twelve months ended December 31, 2003 Expanded distribution strengths Broader specialty pharmaceutical and disease manageme

  16. Slide 16: AdvancePCS Financial Overview Quarter Ended December 31

    AdvancePCS Financial Overview Quarter Ended December 31, 2003

  17. Slide 17: AdvancePCS Strong Financial Performance

    AdvancePCS Strong Financial Performance Three Months Ended December 31 ($ Millions) 2003 2002 % Chg Earnings $ 54.5 $ 45.0 21.1% EPS $ 0.55 $ 0.46 19.6% EBITDA $ 109.0 $ 95.1 14.6% EBITDA/Adjusted Claim $ 0.78 $ 0.69 13.0% Excluding Merger-related Charges*: Earnings $ 58.1 $ 45.0 29.2% EPS $ 0.58 $

  18. Slide 18: AdvancePCS EBITDA & EBITDA per Claim

    AdvancePCS EBITDA & EBITDA per Claim* ($ millions) EBITDA EBITDA per Claim* Excludes impact of merger-related charges in Q204 and Q304. Slide contains Non-GAAP Financial Measure(s). •EBITDA per claim based on adjusted claims: pharmacy network claims plus mail claims multiplied by 3, as mail claims o

  19. Slide 19: AdvancePCS Cash Flow from Operations

    AdvancePCS Cash Flow from Operations ($ millions) $15 $30 $32 $92 $143 $269 $268 YTD 2004 Capital Expenditures Free Cash Flow

  20. Slide 20: AdvancePCS Debt and Debt/EBITDA

    AdvancePCS Debt and Debt/EBITDA* ($ millions) Debt ( ($ Millions) Debt to EBITDA Debt Debt to EBITDA* * EBITDA based on quarterly reported data annualized (current period multiplied by four). Excludes impact of merger-related charges in Q204 and Q304. Slide contains Non-GAAP Financial Measure(s)

  21. Slide 21: AdvancePCS FY2004 Guidance

    AdvancePCS FY2004 Guidance EPS Guidance*: $2.20—$ 2.22 EPS growth based on guidance*: 29% - 30% * Excludes impact of merger-related charges. *

  22. Slide 22: Caremark Rx Financial Overview Quarter Ended December 31

    Caremark Rx Financial Overview Quarter Ended December 31, 2003

  23. Slide 23: Caremark Strong Financial Performance

    Caremark Strong Financial Performance Three Months Ended December 31 ($ Millions) 2003 2002 % Chg Net Revenues $ 2,442.7 $ 1,851.4 31.9% EBITDA $ 160.0 $ 118.7 34.8% Income-Cont Ops $ 82.5 $ 59.6 38.4% EPS – Cont Operations $ 0.31 $ 0.23 34.8% Operating Cash Flow $ 143.6 $ 100.5 42.9% EBITDA/Adjuste

  24. Slide 24: Consistent EBITDA Growth

    Consistent EBITDA Growth EBITDA & EBITDA per Claim* ($ millions) EBITDA EBITDA EBITDA per Claim* Q403 includes $3.4 million impact of integration planning and relocation expenses. Slide contains Non-GAAP Financial Measure(s). * EBITDA per claim based on adjusted claims: pharmacy network claims plus

  25. Slide 25: Strong Cash Flow

    Strong Cash Flow Cash Flow from Continuing Operations ($ millions) $84 $86 $221 $285 $408 $576 Capital Expenditures Free Cash Flow Slide contains Non-GAAP Financial Measure(s)

  26. Slide 26: Strong Cash Flow has Reduced Leverage

    Strong Cash Flow has Reduced Leverage Caremark Balance Sheet is Flexible 1998 1999 2000 2001 2002 2003 Net Debt Net Debt to EBITDA Net Debt Includes Trade Receivables Sales Facility. Slide contains Non-GAAP Financial Measure(s) -

  27. Slide 27: Caremark 2004 Guidance

    Caremark 2004 Guidance Revenue Growth: 15%—20% EPS*: $1.35—$ 1.37 Assumes Tax Rate = 40%. * Excludes the impact of integration planning expenses and corporate headquarters relocation expenses which are anticipated to total $12 - $15 million.

  28. Slide 28: Strategic Summary

    Strategic Summary Caremark, AdvancePCS and other PBMs play a vital role in the U.S. healthcare system by providing innovative pharmaceutical care programs that enhance the quality of life and health for consumers, while reducing cost. PBMs drive down pharmaceutical costs by employing sophisticated c

  29. Slide 29: Additional Information

    Additional Information Caremark has filed with the SEC a registration statement on Form S-4 that was declared effective by the SEC on February 13, 2004. This registration statement includes a joint proxy statement/prospectus and other relevant documents in connection with the proposed transaction. I

  30. Slide 30: Caremark Rx, Inc. AdvancePCS

    Caremark Rx, Inc. AdvancePCS Investor Presentation March 3, 2004

Advancepcs — Merger or Acquisition (March 2004) on 6ix